{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:44:40Z","timestamp":1777481080324,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2025,4]]},"abstract":"\n Background:<\/jats:title>\n Secondary upper limb lymphedema commonly occurs after breast cancer surgery, for which treatment is limited. 9-cis-retinoic acid (9-cisRA) has been demonstrated to increase lymphangiogenesis without enhancing tumor metastasis but has disadvantages of poor water solubility, ready decomposition in light, instability to heat, and a short half-life.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Based on this, 9-cisRA-Lip with a particle size of roughly 143 nm and high dispersibility was prepared by thin-film dispersion method and verified by Malvern Laser Particle Size Analyzer and electron microscopy.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n In vitro<\/jats:italic>\n , 9-cisRA-Lip demonstrated good biosafety and tumor safety, promoting the proliferation of L929 cells while having no effect on 4T1 and Human Umbilical Vein Endothelial (HUVEC) cells. Compared with 9-cisRA, 9-cisRA-Lip was more effective at stimulating mouse lymphatic endothelial cell (SVEC4\u201310) migration, proliferation, and tube formation.\n In vivo<\/jats:italic>\n , 9-cisRA-Lip-Gel showed good slow release effect. Mice treated with 9-cisRA-Lip-Gel one-time local injection had considerably less tail edema than the control group from day 9 to day 39 postsurgery (\n p<\/jats:italic>\n < 0.05). This may be attributed to the greater capacity of 9-cisRA-Lip to enhance the phosphorylation of\n FGFR3<\/jats:italic>\n (Fibroblast Growth Factor Receptor 3) at\n Tyr 724<\/jats:italic>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n 9-cisRA-Lip-Gel presents a potential treatment option for lymphedema following surgery.<\/jats:p>\n <\/jats:sec>","DOI":"10.1089\/cbr.2024.0177","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T08:45:07Z","timestamp":1732869907000},"page":"210-218","source":"Crossref","is-referenced-by-count":0,"title":["Collagen Hydrogel Loaded With 9-cisRA-Lip Is an Option for Treatment of Secondary Lymphedema after Surgery"],"prefix":"10.1177","volume":"40","author":[{"given":"Min","family":"Yao","sequence":"first","affiliation":[{"name":"General Surgery Department, The Second Affiliated Hospital of Soochow University, Suzhou, China."},{"name":"Department of Breast Surgery, Huzhou Maternity & Child Health Care Hospital, Huzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7009-2073","authenticated-orcid":false,"given":"Jinrong","family":"Wei","sequence":"additional","affiliation":[{"name":"General Surgery Department, The Second Affiliated Hospital of Soochow University, Suzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijie","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Huzhou Maternity & Child Health Care Hospital, Huzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyan","family":"Li","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Nano-Bio Interface, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Qin","family":"Jiang","sequence":"additional","affiliation":[{"name":"General Surgery Department, The Second Affiliated Hospital of Soochow University, Suzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.08.036"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.12529"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000000268"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000491385"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10103-021-03446-3"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/lrb.2013.0016"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjps.2011.01.006"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2021.03.002"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.4252\/wjsc.v12.i7.676"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.03.006"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000001912"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1205306109"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2014.2452"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.030296"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13629"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.3.437"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.7.1499"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.2217\/rme.12.39"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27092902"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867325666171205170339"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/rb\/rbac102"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E05-04-0368"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24097774"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/lrb.2021.0073"},{"issue":"1","key":"e_1_3_6_27_2","first-page":"54","article-title":"Mouse tail models of secondary lymphedema: Fibrosis gradually worsens and is irreversible","volume":"13","author":"Zhou C","year":"2020","unstructured":"Zhou C, , Su W, , Han H, et al. Mouse tail models of secondary lymphedema: Fibrosis gradually worsens and is irreversible. Int J Clin Exp Pathol, 2020; 13(1):54\u201364.","journal-title":"Int J Clin Exp Pathol"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2024.0177","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2024.0177","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2024.0177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:11:35Z","timestamp":1777385495000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cbr.2024.0177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1089\/cbr.2024.0177"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2024.0177","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}